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The self-association of misfolded or damaged proteins into 
ordered amyloid-like aggregates characterizes numerous neuro-
degenerative disorders. Insoluble amyloid plaques are diagnostic 
of many disease states. Yet soluble, oligomeric intermediates in 
the aggregation pathway appear to represent the toxic culprit. 
Molecular chaperones regulate the fate of misfolded proteins 
and thereby influence their aggregation state. Chaperones 
conventionally antagonize aggregation of misfolded, disease 
proteins and assist in refolding or degradation pathways. Recent 
work suggests that chaperones may also suppress neurotoxicity 
by converting toxic, soluble oligomers into benign aggregates. 
Chaperones can therefore suppress or promote aggregation of 
disease proteins to ameliorate the proteotoxic accumulation of 
soluble, assembly intermediates.
Introduction
Many neurodegenerative disorders are characterized by the 
misfolding and subsequent aggregation of toxic proteins. Alzheimer, 
Parkinson, and the glutamine-encoding expansion diseases are 
examples of conformational disorders which show late onset symp-
toms of progressive neuronal dysfunction and eventual neuronal 
loss within certain brain regions.1 The disease-causing protein can 
adopt aberrant conformations due to age or stress which enables 
its aggregation and ultimate accumulation in amyloid fibrils 
(Fig. 1).2,3 Amyloids share a β-sheet-rich, fibrillar protein confor-
mation in which the β-sheets stack parallel or anti-parallel to one 
another and run perpendicular to the fiber axis.4,5 Numerous 
pathogenic substrates as well as yeast prion proteins can exist in 
alternate, amyloid-like states that are characterized by a defined set 
of biochemical parameters including the ability to bind indicator 
dyes such as Thioflavin or Congo Red as well as resistance to 
both protease digestion and detergent solubilization.6 Though the 
appearance of amyloid is diagnostic of the disease state, the extent 
of amyloid accumulation often does not correlate with the disease 
symptoms.5,7 In fact, a wide variety of organisms utilize functional 
forms of amyloid-like structures to perform important cellular 
processes such as phenotypic adaptation in yeast8-10 and melanin 
synthesis in humans.11 These and other lines of evidence suggest 
that amyloid formation per se is not toxic but may represent a 
benign byproduct or even a protective mechanism.12-14
Soluble intermediates in the amyloid assembly pathway appear 
to represent the toxic species.7,15 Relatively little is known about 
the exact nature of the assembly intermediates due to their dynamic 
structure (Fig. 1). Antibodies generated against the Aβ42-peptide 
(proteolytically cleaved peptide from the Amyloid Precursor 
Protein, APP, and a causative agent for Alzheimers disease) could 
recognize assembly intermediates formed by numerous amyloido-
genic substrates and buffer their cytotoxicity.15 Subsequent work 
demonstrated that the same conformational-specific antibodies 
could selectively inhibit spontaneous amyloid formation of yeast 
prions in vitro.16,17 Thus, amyloid assembly intermediates, which 
include soluble oligomers, do exhibit common conformation-
dependent structures that are unique to the intermediates regardless 
of the amino acid sequence.
The accumulation of oligomeric amyloid assembly interme-
diates closely correlates with cell death7 and distinct clearance 
pathways maintain the proteotoxic oligomers at low levels.18 This 
can be accomplished by either solubilizing the aggregation-prone 
substrate or driving its assembly into higher-ordered amyloid-like 
aggregates. The ability to promote aggregation does not necessarily 
represent the cell’s primary means of clearance but may provide 
backup pathways when solublization machinery has become 
compromised by age or environmental insult.18 The nature and 
identity of the unfavorable interactions between the soluble 
oligomers and other cellular components is just being defined 
and may result in transcriptional deregulation,19-21 proteasomal 
inactivation,22 aberrant signaling23 or membrane damage.24-26 
It should be noted that disease proteins associated with confor-
mational disorders perform a wide variety of cellular functions 
and scenarios may exist where protein species other than amyloid 
assembly intermediates represent the predominant toxic species.
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hydrophobic peptides which are normally buried in the core of 
natively folded proteins but become solvent-exposed in misfolded 
states.33 The polypeptide binding domain of Hsp40 binds non-
native proteins and delivers them to Hsp70.34,35 The ability of 
Hsp70 to bind the misfolded substrate is tightly regulated through 
an ATP hydrolytic cycle. Once in a complex with Hsp70, the 
J-domain of Hsp40 stimulates ATP hydrolysis on Hsp70 which 
promotes a conformational change in the Hsp70 substrate-
binding domain and increases its binding affinity for the misfolded 
substrate.36-38 Hsp40 is liberated from the Hsp70:substrate 
complex following ATP hydrolysis yet it is unclear how co-chap-
erone release occurs. The substrate in complex with Hsp70 can be 
properly refolded, marked for degradation via Hsp70 coordination 
with degradation machinery, or released to re-enter this binding 
cycle. The substrate remains tightly bound to Hsp70 until ADP 
is exchanged for ATP via a diverse class of nucleotide exchange 
factors (NEF).39 It is in this manner that cooperation between 
Hsp40 and Hsp70 prevents the proteotoxic accumulation of 
misfolded, aggregation-prone proteins.
The involvement of nucleotide exchange factors (NEF) adds 
yet another level of regulation to the Hsp70 system. This diverse 
family of exchange factors is critical for the functional cycle of 
Hsp70 because they replace ADP for ATP on Hsp70 and trigger 
substrate release.39 Well characterized NEFs include the bacterial 
GrpE, which facilitates nucleotide dissociation from the Hsp70 
(DnaK),37,40 and the BAG family of eukaryotic proteins which 
are NEFs for different cytosolic Hsp70s.41 A third family of 
proteins which possess nucleotide exchange activity including the 
cytosolic Fes1 and ER luminal Sls1 in Saccharomyces cerevisiae,42,43 
and the human ortholog HspBP1 (Hsp70 binding protein 1).44 
All cells contain quality control machinery termed 
molecular chaperones to maintain the appropriate folding 
state of proteins. Many of these molecular chaperones 
have been termed Heat-Shock Proteins (HSP) due to their 
increased expression upon heat treatment of cell and have 
been divided into six major families including HSP100, 
HSP90, HSP70, HSP60, HSP40 and the small HSPs.27 
Chaperones recognize misfolded protein conformers and 
ultimately coordinate the appropriate folding or degra-
dation pathways. As the first line of defense against 
conformational disorders, chaperones maintain the solu-
bility of misfolded, disease-related substrates by directly 
binding to non-native conformers or disassembling aggre-
gates formed by the disease protein.27 Alternatively, recent 
evidence suggests that chaperones can also promote 
aggregation and thereby prevent the toxic accumulation 
of amyloid assembly intermediates.13,28 Herein we discuss 
how molecular chaperones manage proteotoxic misfolding 
events of numerous amyloidogenic substrates.
Molecular Chaperones Antagonize Aggregation of 
Disease Proteins
Chaperones act by multiple means to maintain the 
solubility of disease-causing proteins. Chaperone-mediated 
solubilization can occur in the initial stages of the amyloid 
assembly pathway by preventing the self-association of misfolded, 
disease proteins into toxic, oligomeric intermediates. Alternatively, 
chaperones also act later in the assembly pathway to dismantle 
amyloid-like aggregates and resolubilize the disease protein. Thus 
chaperone intervention can either maintain or generate disease 
protein monomers which can be properly refolded or marked for 
degradation by the ubiquitin-proteasome system or autophagy 
pathways. This reduces the flux of misfolded, disease proteins 
through different stages of the amyloid assembly pathway and 
decreases the cellular concentration of proteotoxic assembly inter-
mediates.
Chaperones prevent disease proteins from assembling into 
amyloid-like aggregations. Chaperone machinery can act early in 
the amyloid assembly pathway by recognizing misfolded, disease 
proteins and subsequently preventing their aggregation. The Hsp70 
chaperone system has been well-defined in its role of preventing 
the assembly of different, disease-causing proteins into amyloid-
like aggregates.27,29 The Hsp70 family of chaperone proteins is 
abundantly expressed throughout the cell and contains 11 known 
isoforms in humans.30 Though not as abundant as its Hsp70 
partner, the Hsp40 co-chaperone (also referred to as J-proteins 
due to their highly conserved J-domain) represent a more diverse 
family of proteins which contain 41 isoforms in humans and are 
present in most every intracellular compartment.31 The structural 
and functional diversity of Hsp40 co-chaperones provide specific 
substrate recognition properties for the Hsp70 work horse.32
The misfolding of disease proteins can arise from numerous 
intrinsic or environmental stresses3 and Hsp70 cooperates with 
different Hsp40 co-chaperones to ultimately recognize and refold 
the non-native protein conformers (Fig. 2). Hsp40 can bind 
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Figure 1. Schematic representation of the amyloid assembly pathway. A disease 
causing protein can adopt a non-native conformation due to intrinsic and/or envi-
ronmental stress. The misfolded, disease protein can then self-associate into differ-
ent intermediate structures such as detergent-soluble oligomers and/or protofibrils 
whose intracellular accumulation correlate with cell death. In this model, we specu-
late about the structural properties of the ill-defined intermediates. Alternatively, the 
misfolded protein can accumulate as non-specific, amorphous aggregates. The for-
mation of amyloid seeds drives the autocatalytic conversion of native and misfolded 
protein monomers into β-sheet-rich, amyloid aggregates.
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Hsp70, Ssa1, or the Hsp40, Ydj1, inhibit 
the formation of large, detergent-insoluble 
aggregates by an expanded-polyQ protein 
containing the N-terminal sequence of the 
huntingtin protein, the causative gene for 
Huntington disease.54 Ydj1 also reduced the 
aggregation of the Q/N-rich prion domain 
of the yeast prion, Rnq1, which correlated 
with its ability to suppress prion toxicity.55 
Elevated expression of another yeast Hsp40, 
Sis1, reduced the aggregation of expanded-
polyQ Htt protein and suppressed toxicity 
in [psi-] yeast, which are void of the amyloid-
like [PSI+] prion.56 Hsp70 and Hsp40 have 
also been shown to suppress the aggre-
gation and toxicity of numerous other 
disease-causing proteins including mutant 
superoxide dismutase 1 (SOD),57 the caus-
ative gene for familial amyotrophic lateral 
sclerosis, and α-synuclein,58 the causative 
gene for Parkinson disease. Thus, the ability 
of Hsp70 and Hsp40 to prevent assembly of 
amyloid-like aggregates and suppress cyto-
toxicity extends to numerous disease-causing 
proteins in a variety of model organisms.
Molecular chaperones solubilize protein 
aggregates. Chaperones can act later in the 
aggregation pathway to disassemble amyloid-
like particles. Although it is unclear whether 
mammalian cells possess this disaggregation 
activity, fungi, plants and bacteria express 
the AAA ATPase protein remodeling factor, 
Hsp104 (ClpB in E. coli).59 The hexameric Hsp104 works syner-
gistically with the Hsp70 chaperone system to not only resolubilize 
misfolded substrates, but to also restore their proper function.60 
Interestingly, normal Hsp104 function is required in a yeast model 
to maintain different prion proteins in their amyloid-like prion 
conformation61-64 by generating small prion seeds via fragmenta-
tion of larger prion aggregates which enables new rounds of prion 
propagation.65 Further in vitro studies demonstrated that Hsp104 
couples ATP hydrolysis with the rapid disassembly of amyloid-like 
fibers and oligomeric intermediates formed by the yeast prions 
[PSI+] and [URE3].17,66 Thus, it is not surprising that Hsp104 
overexpression was able to efficiently solubilize amyloid-like aggre-
gates formed by the expanded-polyQ huntingtin (Htt) fragment 
and reduce cell death in a yeast model.67 Yet removal of Hsp104 
via gene deletion also subdued the toxicity caused by overexpres-
sion of the expanded-polyQ Htt fragment.68 Thus, Hsp104 may 
indirectly affect polyQ aggregation and toxicity in yeast by acting 
through the yeast prions, [PSI+] and/or [RNQ+] (also termed 
[PIN+]63), which can serve as Q/N-rich templates to alter the 
conformation of the expanded-polyQ protein into an aggregation-
prone, toxic form.56,68,69
To clarify the role of Hsp104 in polyQ aggregation and toxicity, 
the yeast Hsp104 chaperone was introduced into a number of higher 
Interestingly, other molecular chaperones are capable of nucleotide 
exchange on Hsp70. The yeast Hsp110, Sse1, regulates nucleotide 
exchange on different cytosolic Hsp70s,45 while the Hsp170, 
Lhs1, stimulates nucleotide exchange of the ER Hsp70, Kar2.46 
Sse1 is a particularly interesting exchange factor because its activity 
in yeast is required for the propagation of the [URE3] prion,47 as 
well as the formation and propagation of the [PSI+] prion.48 The 
recent findings which implicate Sse1 in the formation and propa-
gation of amyloid-like prions may establish a better understanding 
of how nucleotide exchange on Hsp70 affects amyloid dynamics. 
Thus, the cell can utilize this diverse family of NEFs to regulate the 
different activities of Hsp70 in distinct subcellular compartments.
The ability of Hsp70 and Hsp40 to suppress the assembly of 
disease proteins into amyloid-like aggregates has been well docu-
mented in numerous model systems,27 yet only a few examples 
will be discussed. Glutamine-encoding repeats within a set of 
unrelated proteins are the cause of at least nine different late onset 
neurodegenerative disorders.49,50 Elevating intracellular pools of 
Hsp70 as well as Hsp40 reduce expanded-polyQ aggregate forma-
tion and suppressed toxicity in cultured cells.51-53 Due to the 
high conservation of chaperone machinery between eukaryotic 
cells, Saccharomyces cerevisiae has emerged as a model system to 
study protein aggregation and toxicity. Overexpression of the yeast 
Figure 2. Hsp70-Hsp40 hydrolytic cycle for the binding and refolding of non-native proteins. A 
native protein can adopt a non-native conformation. Hsp40 co-chaperones can recognize the 
misfolded protein and bind it via its polypeptide binding domain. Hsp40 delivers the non-native 
substrate to Hsp70 and its J-domain stimulated ATP hydrolysis on Hsp70. This promotes a con-
formational change in Hsp70 via closure of the lid domain and increases the binding affinity of 
Hsp70 for the substrate. Hsp70 along with other cellular components not shown in this model can 
assist in the proper refolding of the substrate. Nucleotide exchange factors (NEF) release ADP and 
load ATP back onto the nucleotide binding domain of Hsp70 which promotes substrate release.
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or aggregated proteins and target them via the KFERQ motif 
to lysosomes for degradation. The causative agent in Parkinson 
disease, α-synuclein, possesses a pentapeptide sequence which 
is consistent with the CMA recognition motif and targets the 
disease protein to lysosomes.85 The pathogenic A53T and A30P 
mutations in α-synuclein were capable of binding the lysosomal 
receptors but inhibited both their own degradation as well as 
other substrates. Additionally, CMA has also been linked to 
polyQ-expanded huntingtin toxicity through the small heat shock 
protein, HspB8 and Bag3. In cultured cells, elevated expression 
of HspB8 prevented the intracellular accumulation of polyQ-
expanded huntingtin protein.86 Subsequent work demonstrated 
that HspB8 works in complex with Bag3 to stimulate the degrada-
tion of polyQ-expanded huntingtin protein by macroautophagy.87 
Thus, chaperones can couple their activity with multiple degrada-
tion pathways to remove toxic, disease proteins.
Chaperones Promote Aggregation of Toxic Proteins
Chaperones are also capable of packaging disease proteins into 
tight, amyloid-like aggregates and thereby reducing the accumula-
tion of soluble, oligomeric intermediates. Elevated expression of 
the human Hsp40, Hdj2, increased the aggregation of expanded-
polyQ huntingtin protein in COS-7 cells.88 Subsequent in vitro 
studies demonstrated that purified forms of Hsp70 and Hsp40, 
Hdj1, were able to attenuate polyQ oligomer assembly and drive 
the formation of amyloid-like fibrillar structures.89 These data 
suggest that chaperones can partition disease proteins between 
oligomeric and fibrillar aggregation states. Chaperones other than 
Hsp70 and Hsp40 can take an active role in promoting protein 
aggregation. The proteasomal chaperones, Rpt4 and Rpt6 (AAA 
ATPase subunits of the 19S proteasomal particle), facilitated 
the aggregation of different expanded-polyQ disease proteins, 
huntingtin and ataxin-3, without affecting proteasomal degrada-
tion.90 Furthermore, in vitro reconstitution experiments showed 
that purified 19S proteasomal particles enhanced aggregation of 
expanded-polyQ huntingtin protein.90 Thus, a number of molec-
ular chaperones can promote the assembly of disease proteins into 
amyloid-like aggregates.
Chaperone-mediated aggregation reduces proteotoxicity. 
Recent work has begun to link chaperone-mediated aggregation of 
toxic proteins with suppression of toxicity. The chaperonin TriC 
complex was identified as potent suppressor of polyQ-mediated 
toxicity in C. elegans.91 This family of chaperonins form multi-sub-
unit, cage-like structures that sequester non-native proteins92 and 
work alongside Hsp70 chaperone systems to promote substrate 
refolding in the cytosol upon rounds of ATP hydrolysis.93,94 
Substrate refolding occurs within the central cavity of the chap-
eronin complex and substrate release occurs after folding is 
complete.95 Interestingly, reducing the cellular concentration of 
TriC resulted in the accumulation of low-molecular weight, soluble 
oligomers by polyQ-expansions which correlated with toxicity in 
cell culture lines and yeast.28,96,97 One group demonstrated by 
size exclusion chromotagraphy that toxic oligomers were approxi-
mately 200 kDa in size,98 yet the chaperonin complex remodeled 
the polyQ-expansions into higher molecular weight aggregates 
eukaryotes and retained its ability to remodel amyloid-like assemblies. 
In a C. elegans model, expression of Hsp104 reduced the aggregation 
of expanded-polyQ proteins and abrogated  developmental delays.70 
Similarly in a rat model, the presence of Hsp104 suppressed 
expanded-polyQ toxicity in a manner which correlated with altered 
distribution and number of the polyQ assemblies.71 The small heat 
shock proteins, Hsp26 in yeast and Hsp27 in rats, were identified 
as potentiators for Hsp104-mediated suppression of polyQ aggrega-
tion and toxicity.67,71 Utilizing a Parkinson disease model in rats, 
Hsp104 was also shown to antagonize the formation oligomeric 
intermediates and amyloid fibers by α-synuclein which reduced 
dopaminergic degeneration.72 Thus, molecular chaperones can act 
at multiple stages in the aggregation pathway to both coordinate 
the disassembly of amyloid-like aggregates and prevent the self-
association of non-native protein monomers.
Molecular chaperones participate in the degradation of 
proteotoxic substrates by the ubiquitin-proteasome system or 
chaperone-mediated autophagy. Under certain conditions, chap-
erone machinery cannot repair the misfolded protein and must 
coordinate its degradation by either the ubiquitin-proteasome 
pathway or lysosomal-mediated autophagy. CHIP (carboxy 
terminus of Hsc70-interacting protein) is a versatile protein 
that acts as a co-chaperone to Hsc70 (Heat shock cognate 70) 
or Hsp70, possesses intrinsic chaperone activity in its own right 
and functions as an E3 ligase to mediate the transfer of polyubiq-
uitin chains to misfolded substrates.73-75 The Hsp70 interacting 
protein, Bag2 (Bcl2-associated athanogene 2), can inhibit the 
ubiquitin ligase activity of CHIP and promote substrate refolding 
by Hsp70.76,77 Overexpression of CHIP increased the ubiquitina-
tion and degradation of expanded-polyQ huntingtin and ataxin-3, 
the causative gene for Spinocerebellar ataxia type 3 (SCA3).78 This 
subsequently reduced polyQ aggregation levels and suppressed cell 
death. The suppressive activity by CHIP overexpression became 
more prominent when Hsc70 levels were also elevated. Similar 
results were obtained which demonstrated CHIP’s ability to reduce 
aggregation of expanded-polyQ substrates and suppress cell death 
in transfected cell lines, primary neurons and zebrafish models.79 
Therefore, CHIP along with other cofactors can partition Hsp70 
substrates between refolding and degradation pathways.
The autophagy pathway represents a mechanism independent 
of the ubiquitin-proteosome system which participates in the 
intracellular bulk degradation of organelles as well as misfolded 
and aggregated proteins. Autophagy entails the packaging/engulf-
ment of cytoplasmic contents into autophagosome vesicles which 
fuse with lysosomes, wherein the contents are degraded.80 Loss of 
autophagy in mice via disruption of ATG5 manifested features 
characteristic of neurodegeneration even in the absence of any 
disease-associated mutant proteins.81 Molecular chaperones have 
been shown to participate in the recognition and subsequent 
packaging of misfolded proteins into autophagasomes which has 
become termed chaperone-mediated autophagy (CMA).82 CMA 
involves the selective targeting of proteins containing a KFERQ 
peptide motif to lysosomes.83 The rate-limiting step in CMA 
involves chaperone/cargo binding to the lysosomal receptor, 
Lamp2a.84 In this manner, chaperones can recognize misfolded 
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of native Rnq1 into a toxic form.13 
Elevating Sis1 levels was able to 
suppress Rnq1 toxicity in a manner 
that correlated with increased forma-
tion of [RNQ+] prion assemblies and 
decreased amounts of soluble Rnq1. 
Point mutations (Rnq1 L94A) within 
the Sis1 binding site of Rnq1 enabled 
it to assume an aberrant confor-
mation which formed SDS-soluble 
aggregates and became toxic in [rnq-] 
cells. Interestingly, Sis1 overexpres-
sion was able to detoxify excess Rnq1 
L94A in [RNQ+] cells yet was unable 
to suppress Rnq1 L94A toxicity in 
[rnq-] cells. Therefore, Sis1 detoxifi-
cation requires [RNQ+] prion seeds so 
that nascent Rnq1 can be efficiently 
packaged into benign, amyloid-
like aggregates. Inefficiencies in the 
[RNQ+] prion assembly pathway due 
to compromised Sis1 activity exacer-
bated cell death.
The molecular mechanism by 
which chaperones facilitate Rnq1 
assembly into amyloid-like prions is 
not clear. Sis1 was previously shown 
to work in concert with Hsp104 to 
mediate the fragmentation of larger 
[RNQ+] prion aggregates.104 This generates more [RNQ+] prion 
seeds and more nucleation points to further drive the autocata-
lytic conversion of nascent Rnq1 into the prion conformer. The 
Ssa subclass of Hsp70 chaperones positively affects the formation 
and propagation of amyloid-like [PSI+] prions in yeast105-107 
(discussed in a previous Prion review article).108 Yet the role of 
Hsp70 in [RNQ+] prion assembly remains elusive. It does appear 
that [RNQ+] prion shearing alone is not sufficient to suppress Rnq1 
toxicity as overexpression of Hsp104 or different Hsp70 members 
was unable to suppress Rnq1 toxicity like excess Sis1.13 Therefore, 
we suggest that Sis1 may perform an additional function as an 
elongation factor in the [RNQ+] prion assembly process (Fig. 3). 
Sis1 was shown to bind a region of Rnq1 outside the Q/N-rich 
prion domain13 in equimolar ratios.109 Thus Sis1 may coat [RNQ+] 
prions and facilitate the stable association of nascent Rnq1 with 
[RNQ+] prions which would subsequently promote its efficient 
conversion into the growing amyloid-like [RNQ+] aggregate. Yet it 
is difficult to judge the relative importance of Sis1 action in frag-
mentation versus elongation of [RNQ+] prions.
Distinct signaling pathways facilitate protein detoxification 
via opposing mechanisms. Cells can manage the proteotoxic 
accumulation of soluble, oligomeric species by both disaggregation 
and aggregation methods. C. elegans have become a valuable tool 
to dissect the dynamics of amyloid assembly pathways in aging 
organisms. Distinct signaling pathways exist which both prevent the 
formation of amyloid aggregates as well as promote efficient amyloid 
around the 500 kDa size range.28 The ability of the chaperonin 
complex to remodel polyQ-expanded disease proteins worked 
synergistically with Hsp70, Ssa1 and Hsp40, Ydj1. In contrast, 
studies in [psi-] yeast demonstrate that excess Ydj1 increased aggre-
gation of expanded-polyQ Htt, yet enhanced toxicity.56 Though 
these data seems contrary to the work done with TriC, the nature 
and size of the polyQ aggregates may differ between experimental 
conditions and account for whether the polyQ protein elicits a 
toxic or benign outcome. Additionally, cellular factors such as 
endogenous prions add to complexity of how chaperone networks 
buffer the accumulation of expanded-polyQ aggregates in a yeast 
model. Nevertheless, this provides correlative evidence that chap-
eronin complexes can not only solubilize their substrates but also 
promote the efficient packaging of proteotoxic species into benign 
aggregates.
Related studies in yeast have recently demonstrated the protec-
tive effects of Hsp40-mediated aggregate formation. The Hsp40, 
Sis1, is an essential chaperone99 that participates in protein 
refolding,100 protein translocation101 and translation initiation.102 
Sis1 activity is also required to maintain the Rnq1 yeast prion in its 
[RNQ+] amyloid-like, prion conformation.103 Endogenous Rnq1 
is not toxic to yeast yet modest elevation of Rnq1 levels induced cell 
death.13 Rnq1 toxicity is dependent on the presence of pre-existing 
[RNQ+] prions as elevated Rnq1 levels are not toxic to [rnq-] cells 
in which the [RNQ+] prion conformer is absent. Thus, [RNQ+] 
prion seeds provide a template which can alter the conformation 
Figure 3. Roles for Sis1 in [RNQ+] prion assembly. The [RNQ+] prion acts as a template to alter the confor-
mation of native Rnq1 into an assembly competent monomer. Sis1 promotes the appropriate packaging of 
templated Rnq1 monomers into higher-ordered [RNQ+] prions via a fragmentation and elongation model. 
Inefficiencies in this assembly process by Rnq1 overexpression or Sis1 depletion enable templated mono-
mers to accumulate as soluble, proteotoxic species.
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assembly. The heat shock factor-1 (HSF-1) signaling pathway 
promoted the solubilization of toxic, Aβ1-42 assemblies.
18 HSF-1 
activity is induced by a variety of stress signals including  heat-shock 
which subsequently promotes the expression of numerous chap-
erones.110-112 In contrast, the DAF-16 signaling pathway appears 
to promote efficient assembly of Aβ1-42 peptides into amyloid 
particles. The FOXO transcription factor, DAF-16,113,114 is a 
downstream target of insulin/insulin growth factor (IGF)-1-like 
signaling pathway which regulated life span and youthfulness in 
worms, flies and mammals.115 Although HSF-1 and DAF-16 
signaling pathways promote longevity and cell survival, they appear 
to act by opposing mechanisms to accomplish this feat.
Conclusions
Molecular chaperones can intervene at multiple points in the 
amyloid assembly pathway to buffer the proteotoxic accumulation 
of misfolded protein intermediates. As a first line of defense, chap-
erones networks can coordinate the solubilization and subsequent 
refolding or degradation of different toxic proteins. Alternatively, 
the cell possesses a second line of defense which can package 
misfolded proteins into benign aggregates and thereby minimize 
the cell’s exposure to the toxic assembly intermediates. Although 
the formation of amyloid-like aggregates appears to protect cells 
against protein misfolding events, the gradual stockpiling of 
amyloid fibrils into intra- and extra-cellular plaques can clearly 
have a negative impact on normal cellular processes over extended 
periods of time.116-118 Additionally, the general decline in protein 
homeostasis or proteostasis3 by age or chronic stress may compro-
mise chaperone networks2 resulting in the destruction of benign 
aggregates and the generation of soluble, toxic oligomers. Two 
distinct signaling cascades appear to regulate the flux of misfolded, 
amyloidogenic proteins between solubilization and aggregation 
pathways.18 HSF-1 regulates the expression of numerous molec-
ular chaperones111 and can antagonize aggregation through control 
of the integrated chaperone network. However, it is unclear in 
the DAF-16 signaling pathway which downstream components 
are involved in the remodeling of misfolded, disease proteins into 
ordered aggregates. Sis1 and the chaperonin complex were shown 
to drive protective aggregate formation, yet both proteins histori-
cally act to suppress non-specific aggregation.100,119 Therefore, 
different signaling pathways such as DAF-16 and HSF-1 may 
enable an individual chaperone such as Sis1 or the TriC chaperonin 
complex to perform opposing functions on misfolded proteins. 
Alternatively, the disease substrate may possess intrinsic, structural 
properties which determine the action of the interacting chap-
erone. Further studies will elucidate the means by which opposing 
chaperone activities are regulated at a molecular and cellular level.
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